SuperGen Withdraws Drug Application  NEW YORK (Reuters) - SuperGen Inc. on Monday said it has  withdrawn an application to market its pancreatic cancer drug  in the United States due to insufficient data, casting a cloud  on the drug's future in the world's biggest market and sending  the company's shares down as much as 16 percent.